AMGN · Earnings call · 2026Q3T · Full report

Rare Disease Product Demand

AMGEN INC · 2026-11-03 · Importance 65 · Surprise 48 · No source text

The rare disease portfolio grew 21% year-over-year to $1.6 billion, reflecting demand from additional indications and international expansion. UPLIZNA sales rose 191% to $451 million, with demand across approved indications and U.S. growth in generalized myasthenia gravis; new and continuing U.S. patients in gMG increased 45% quarter-over-quarter. Adoption included both biologic-naive patients and patients transitioning from other therapies, while UPLIZNA had launched in 25 markets outside the United States. TEPEZZA sales declined 6% to $526 million, while international adoption continued to build, particularly in Japan, and the product had launched in more than 20 countries.

Key facts

• UPLIZNA sales increased 191% year-over-year to $451 million in Q3 2026.
• Amgen's rare disease portfolio grew 21% year-over-year to $1.6 billion in Q3 2026.
• TEPEZZA generated $526 million in Q3 2026 sales, down 6% year-over-year.
• U.S. UPLIZNA new and continuing patients in generalized myasthenia gravis increased 45% quarter-over-quarter.
• Amgen said daxdilimab Phase II results in discoid lupus showed 20 to 50 people per 100,000 with the disease, and 5% to 10% progress to SLE.

Impact estimates